Prelude Capital Management, LLC Puma Biotechnology, Inc. Transaction History

Prelude Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$8.75 - $12.85 $1,050 - $1,542	-120 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$12.3 - $35.76 $3,444 - $10,012	-280 Reduced 70.0%	120 $2,000
Q4 2018 Feb 14, 2019	BUY	$20.07 - $46.7 $8,028 - $18,680	400 New	400 $8,000
Q2 2018 Aug 14, 2018	SELL	$48.3 - $68.25 $421,320 - $595,344	-8,723 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$59.7 - $99.25 $217,069 - $360,873	-3,636 Reduced 29.42%	8,723 $594,000
Q4 2017 Feb 14, 2018	BUY	$93.85 - $132.45 $1.16 Million - $1.64 Million	12,359	12,359 $1.22 Million

30.5M

73.5K

18.5K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $114M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.